Bausch Health Companies Inc. (NYSE:BHC) Shares Purchased by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership grew its position in Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 46.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,770,793 shares of the company's stock after purchasing an additional 1,510,445 shares during the period. Arrowstreet Capital Limited Partnership owned approximately 1.32% of Bausch Health Companies worth $38,501,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. Tobam boosted its holdings in Bausch Health Companies by 10.4% in the fourth quarter. Tobam now owns 15,034 shares of the company's stock valued at $121,000 after purchasing an additional 1,422 shares during the last quarter. American Century Companies Inc. boosted its stake in shares of Bausch Health Companies by 10.6% in the fourth quarter. American Century Companies Inc. now owns 27,236 shares of the company's stock worth $220,000 after buying an additional 2,600 shares during the last quarter. Blair William & Co. IL boosted its stake in shares of Bausch Health Companies by 3.2% in the fourth quarter. Blair William & Co. IL now owns 84,707 shares of the company's stock worth $683,000 after buying an additional 2,622 shares during the last quarter. Sanders Morris Harris LLC grew its holdings in Bausch Health Companies by 16.0% during the fourth quarter. Sanders Morris Harris LLC now owns 28,975 shares of the company's stock worth $234,000 after acquiring an additional 4,000 shares during the period. Finally, Kendall Capital Management raised its position in Bausch Health Companies by 43.4% during the fourth quarter. Kendall Capital Management now owns 17,995 shares of the company's stock valued at $145,000 after acquiring an additional 5,445 shares in the last quarter. 78.65% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Bausch Health Companies Stock Down 1.4 %

Shares of BHC stock traded down $0.08 during trading hours on Monday, hitting $5.26. 4,043,954 shares of the company's stock were exchanged, compared to its average volume of 2,737,684. The firm has a 50 day moving average of $6.86 and a two-hundred day moving average of $7.67. Bausch Health Companies Inc. has a fifty-two week low of $3.96 and a fifty-two week high of $10.46. The firm has a market cap of $1.93 billion, a P/E ratio of -43.79, a P/E/G ratio of 0.37 and a beta of 0.43.

Bausch Health Companies (NYSE:BHC - Get Free Report) last posted its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.44). The company had revenue of $2.56 billion for the quarter, compared to analyst estimates of $2.51 billion. Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. On average, equities analysts forecast that Bausch Health Companies Inc. will post 4.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on BHC shares. Royal Bank of Canada lowered their price objective on Bausch Health Companies from $9.00 to $8.50 and set a "sector perform" rating on the stock in a research report on Monday. Jefferies Financial Group reissued a "hold" rating and set a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $7.17.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.